Articles On Resapp Health (ASX:RAP)

Local stocks made a cautious start to the week, following a fairly volatile trading period last week as jitters stemming from rising bond yields dimmed risk sentiment on global markets. The ASX 200 opened in the red before clawing back some...

ResApp Health (RAP) completes recruitment for its US-based SARS-CoV2 clinical study, COVID-Cough The trial collects audio cough recordings and symptoms for 122 PCR-confirmed COVID-19 positive cases and 139 negative cases The clinical study...

ResApp Health’s (RAP) smartphone application, ResAppDx, goes live on Indonesian online telehealth platform Alodokter ResAppDx is a smartphone-based acute respiratory disease diagnostic test, for use in telehealth, emergency department and...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

ResApp Health (RAP) has entered into a three-year distribution agreement with Sanrai International, assisting RAP’s reach in emerging markets Sanrai is a distributor of innovative medical device products with long-standing relationships in...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

Digital health company ResApp Health (ASX:RAP) has announced the establishment of a COVID-19 Scientific Advisory Board.

Digital health company ResApp (ASX:RAP) has announced TGA clearance and CE Mark certification for its standalone cough counter smartphone application.

The ResApp Health Ltd (ASX: RAP) share price ticked up a notch towards the end of Monday’s market session. This followed the digital health company’s announcement that it has secured regulatory approval for its cough counter smartphone app...

Highlights The ASX 200 index fell over 1.1% to 7,201.7 in early trade. The World Health Organization (WHO) had classified Omicron variant as "a variant of concern”. The financial space, A-REITs and energy sectors have all taken a hit...

ResApp Health (RAP) achieves Australian Therapeutics Good Administration clearance and CE Mark certification for its cough counter smartphone application The cough counter tracks cough frequency using ResApp’s machine learning algorithms t...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

ResApp Health (RAP) has completed recruitment for its COVID-19 study in India ahead of schedule The company’s trial enrolled 337 patients in India, including over 200 COVID-19 positive cases, with inpatients providing cough sound samples d...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

ResApp Health (RAP) locks in a three-year licensing agreement with Janssen Pharmaceutica NV for use of its ResAppDx technology in a trial The study will see ResAppDx used by Janssen to assess the respiratory symptoms of a group of patients...

The ASX 200 Health Index (XHJ) is up by 1.5% at the time of writing, compared to the broader index which is up by 0.40%. Mesoblast (ASX:MSB) jumped 10% after reporting data from its Phase 3 trial of rexlemestrocel-L in chronic heart failure...

ResApp Health (RAP) receives approval to modify its US-based SARS-CoV2 clinical study The Institutional Review Board (IRB) approved modifications to COVID-Cough, ResApp’s COVID-19 clinical trial, to allow recruitment at in-person testing c...

Digital health company ResApp Health (RAP) updates the market on activities undertaken in the September quarter Europe’s Medgate has penned a licence deal with ResApp to integrate the ResAppDx smartphone app into its services across Europe...

ResApp Health (RAP) completes the recruitment ahead of schedule for its Indian COVID-19 clinical study A total of 100 COVID-19 positive patients have been recruited and given the fast recruitment, the trial has been expanded to 200 positi...

ShareCafeDiagnosing COVID Via a Smartphone App   ResApp Health (ASX: RAP) is developing digital healthcare solutions to assist doctors and empower patients to diagnose and manage respiratory disease. Diagnosing COVID Via a Smartphone AppSt...

Digital health company ResApp Health (ASX:RAP) has submitted a 510(k) premarket notification to the US FDA for SleepCheckRx, a prescription-only, software-as-a-medical device smartphone application for at-home sleep apnoea screening...

ResApp Health (RAP) submits a 510(k) pre-market notification to the US Food and Drug Administration (FDA) for its obstructive sleep apnoea platform The company says the FDA clearance would unlock a substantial market opportunity for ResApp...

The ResApp Health Ltd (ASX: RAP) share price is on the move again today following yesterday’s meteoric rise. The digital health company provided another positive release to the ASX today. At the time of writing, ResApp shares are fetching...

The ASX 200 health stocks index (XHJ) fell by 0.90% at the time of writing, compared to the broader ASX 200 index which fell by 0.40%. Medicinal cannabis play, Cronos Australia (ASX:CAU), has jumped by 19% in morning trading, after announci...

The ResApp Health Ltd (ASX: RAP) share price has been trending among investors, following its meteoric rise in recent memory. At the time of writing, the digital health company’s shares are up an astonishing 18.92% to 8.8 cents. This means...

The ASX regained some lost ground from yesterday’s bloodbath, but closed this week lower than what it began. The ASX 200 gained 0.5% to close at 7,407 points while the ASX Emerging Companies Index rose 2.45% to close at 2,469. Most sectors...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

Highlights EBOS (ASX:EBO) acquires Sentry Medical to expand into medical consumables Piedmont (ASX:PLL) completes initial investment in IronRidge Knosys (ASX:KNO) completes acquisition of LIBERO The S&P/ASX200 closed lower We...

ShareCafeHidden Gems Webinar Recap – BPH, EX1, RAP & PTX Catch up on the full webinar with presentations from BPH Energy (ASX: BPH), Exopharm (ASX: EX1), RessApp (ASX: RAP) & Prescient Therapeutics (ASX: GSS) Hidden Gems Webinar Re...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

Summary Nutritional Growth Solutions has entered into a non-exclusive supply agreement to launch Healthy Height® in China. Allegra will explore the new coatings manufacturing process with Swinburne’s ARC Training Centre for SEAM and RM...

The ASX had another positive day but, unlike yesterday, held momentum to close at an all time high. The ASX 200 closed at 7,511 points which was an 0.11% gain although the ASX Emerging Companies Index fell 0.63% to 2,226 points. The top sec...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

The ASX rebounded from yesterday’s losses but short of an all time high. The ASX 200 closed at 7,503 points, 0.38% up from yesterday but 6 points behind its intraday high. Meanwhile the ASX Emerging Companies Index gained 0.63% at 2,240 poi...

Summary REA Group (ASX:REA) completes transaction with PropertyGuru BNK Banking (ASX:BBC) announces alliance with Goldman Sachs for A$500m Securitisation Warehouse Westpac (ASX:WBC) to kick-off jab program for Western Sydney The S...

The ResApp Health Ltd (ASX: RAP) share price is flying higher today, up 25%. The company – which provides health care solutions for respiratory diseases via smartphone applications – emerged from Monday’s trading halt this morning. And inv...

The ASX closed in negative territory despite a solid gain in tech stocks. The ASX 200 closed 0.23% down at 7,474 points although the ASX Emerging Companies Index rose 1.06% to close at 2,226 points. Despite tech stocks gaining 4.38%, as inv...

Local markets have made a strong start to the week, with the ASX200 closing 1.34% higher on Monday as some major M&A activity stole the headlines. Gains were led by the tech sector, as Afterpay (ASX:APT) showed its weight by dragging th...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Digital health company ResApp Health (ASX:RAP) has announced the publication of acute exacerbation of COPD data from its Breathe Easy adult clinical study and a new commercial agreement with Australian-based telehealth company Docto...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Summary ASX-listed digital health company ResApp Health has recruited the first participant in its US-based trial to assess the link between cough and COVID-19. Botanix Pharmaceuticals revealed encouraging results from the BTX 1204A Pi...

The market is trading near day’s high at the close, after the Reserve Bank of Australia’s (RBA) maintained status quo in its latest policy announcement and upgraded the country’s GDP growth estimates. The benchmark index ASX 200 was up 35.5...

Summary Digital health player ResApp Health has entered into a non-exclusive distribution agreement with Ilara Health. Recce Pharmaceuticals stated that RECCE® 327 had shown bactericidal activity against ESKAPE pathogens, including the...

The Australian share market continued to trade in positive on Tuesday afternoon, owing to favourable global cues, with the benchmark index ASX 200 adding 21.9 points or 0.31% to trade at 7,050. Seven of 11 sectors were trading in green, wh...

The ResApp Health Ltd (ASX: RAP) share price is racing higher in mid-morning trade. This comes after the company announced a new agreement to accelerate sales in ResAppDx. At the time of writing, the digital health company’s shares are fet...

The capital raisings boom on the ASX is continuing in 2021 with nearly $10 billion raised in the first four months of the year. Across 325 deals, ASX companies have raised $9.878 billion in capital amidst IPOs, placements and rights issues....